Key Drivers
- High profitability
- Strong liquidity
- Heavy capex
AIAI Summary
RDY is shifting from volume generics to higher‑complexity products and biosimilars, turning the investment case into a binary, execution‑dependent thesis where abatacept BLA approval and early commercial traction are the key catalysts to validate margin resilience and justify the higher capex/M&A run‑rate. Actionable checklist: watch the abatacept BLA outcome, margin re‑expansion vs Q3 FY26 levels, and FCF relative to ongoing capex/ROIC — approval plus sustained margin improvement = upside, delays or poor ROI = downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Strong liquidity
- •Heavy capex
RDY is highly profitable and well-liquid with conservative leverage, strong free cash flow and premium multiples, but heavy capex/intangible investment and large operating costs are the main risks.
Price Behavior
Key Price Behavior Insights:
- •Below monthly average
- •Recent downward momentum
- •Tight range testing
RDY is in a modest short-term downtrend—trading ~3–4% below its month average with negative momentum from a local high of $14.78 to $13.76, leaving resistance near $14.7–$14.8 and support around $13.7–$13.8.
~7% high–low swing and ~6.9% drop from $14.78 (2026-02-24) to $13.76 (2026-03-20)
Sentiment & News
Key News Insights:
- •Complex generics focus
- •Biosimilars strategy
- •Defensive revenue move
RDY is shifting from low-cost generics toward complex generics and biosimilars to defend revenue amid persistent pricing pressure.
This strategy should help stabilize RDY's margins and revenue growth by targeting higher-barrier, steadier-priced segments
Similar Companies in Healthcare
Other companies in the same sector with AI ratings